Zoltan (Zolt) Arany, MD, PhD is the Samuel Bellet Professor of Cardiology and Director of the Cardiovascular Metabolism Program at the Perelman School of Medicine at the University of Pennsylvania. Dr. Arany graduated Summa Cum Laude from Harvard College. He received his Medical Degree from Harvard Medical School and his doctoral degree from the Harvard Graduate School of Arts and Sciences. After his doctoral studies, Dr. Arany completed internal medicine residency training at the Massachusetts General Hospital, followed by fellowship training in Cardiology at the Brigham and Women’s Hospital, and post-doctoral research fellowship at the Dana Farber Cancer Institute, in Boston. He joined the University of Pennsylvania in 2014.
Dr. Arany’s laboratory focuses on the mechanisms that underlie metabolic pathophysiology in the cardiovascular system. He focuses on linking investigations of cardiac and vascular physiology in model organisms to clinical data and observations, and taking a multidisciplinary approach, spanning from molecular biology and numerous ‘omic approaches to model organisms and human clinical studies. Recent focus in Dr. Arany’s laboratory has included the metabolic changes that underlie heart failure, the role of the vasculature in the development of diabetes, and maternal cardiac disease during and after pregnancy. Dr. Arany is also an active clinical cardiologist, teacher, and mentor, and the current Chair of the Cellular Biology Physiology and Metabolism Graduate Group.
Dr. Arany is a recipient of several awards including the American Heart Association Established Investigator Award in 2012, the Hal Dvorak Young Investigator Award in Translational Research, and the prestigious Inaugural Yale Calabresi Prize in 2014, given to Dr. Arany in recognition for his work on cardiovascular metabolism. He is elected to the American Society of Clinical Investigators, and to the American Association of Physicians. Dr. Arany has published more than 130 research papers in prominent journals such as New England Journal of Medicine, Nature, Cell, Science, PNAS, Cell Metabolism, and Genes & Development. Dr. Arany is regularly invited to speak nationally and internationally on his basic and translational research in cardiovascular metabolism. He has also received a number of teaching and mentoring awards.

Zoltan (Zolt) Arany, MD, PhD is the Samuel Bellet Professor of Cardiology and Director of the Cardiovascular Metabolism Program at the Perelman School of Medicine at the University of Pennsylvania. Dr. Arany graduated Summa Cum Laude from Harvard College. He received his Medical Degree from Harvard Medical School and his doctoral degree from the Harvard Graduate School of Arts and Sciences. After his doctoral studies, Dr. Arany completed internal medicine residency training at the Massachusetts General Hospital, followed by fellowship training in Cardiology at the Brigham and Women’s Hospital, and post-doctoral research fellowship at the Dana Farber Cancer Institute, in Boston. He joined the University of Pennsylvania in 2014.
Dr. Arany’s laboratory focuses on the mechanisms that underlie metabolic pathophysiology in the cardiovascular system. He focuses on linking investigations of cardiac and vascular physiology in model organisms to clinical data and observations, and taking a multidisciplinary approach, spanning from molecular biology and numerous ‘omic approaches to model organisms and human clinical studies. Recent focus in Dr. Arany’s laboratory has included the metabolic changes that underlie heart failure, the role of the vasculature in the development of diabetes, and maternal cardiac disease during and after pregnancy. Dr. Arany is also an active clinical cardiologist, teacher, and mentor, and the current Chair of the Cellular Biology Physiology and Metabolism Graduate Group.
Dr. Arany is a recipient of several awards including the American Heart Association Established Investigator Award in 2012, the Hal Dvorak Young Investigator Award in Translational Research, and the prestigious Inaugural Yale Calabresi Prize in 2014, given to Dr. Arany in recognition for his work on cardiovascular metabolism. He is elected to the American Society of Clinical Investigators, and to the American Association of Physicians. Dr. Arany has published more than 130 research papers in prominent journals such as New England Journal of Medicine, Nature, Cell, Science, PNAS, Cell Metabolism, and Genes & Development. Dr. Arany is regularly invited to speak nationally and internationally on his basic and translational research in cardiovascular metabolism. He has also received a number of teaching and mentoring awards.

Dr. Prof. Luc Bertrand is currently Full Professor in Biochemistry and Regenerative Medicine in the department of Pharmacy and Biomedical Sciences at the University of Louvain (Brussels, Belgium). He is also FNRS Research Director hon. (Fonds National de la Recherche Scientifique, Belgium). He is group leader and co-director of the pole of Cardiovascular Research located in the Institute of Experimental and Clinical Research. His research group aims to understand the relationship between metabolism and cardiac (dys)function in pathologies such as cardiac hypertrophy, heart failure and diabetic cardiomyopathy. He has published over 110 peer-review papers with a H-index of 50. His research is supported by different grants from the Federal and Regional Governments, FNRS, WELBIO and UCLouvain. He was/is board member of several international scientific organizations (Working group of myocardial function of the European Society of cardiology, French Society of Cardiology, Society for Heart and Vascular Metabolism, Fondation de France) and scientific journals (Am. J. Physiol. Heart and Circul. Physiol., PlosONE).

Dr. Prof. Luc Bertrand is currently Full Professor in Biochemistry and Regenerative Medicine in the department of Pharmacy and Biomedical Sciences at the University of Louvain (Brussels, Belgium). He is also FNRS Research Director hon. (Fonds National de la Recherche Scientifique, Belgium). He is group leader and co-director of the pole of Cardiovascular Research located in the Institute of Experimental and Clinical Research. His research group aims to understand the relationship between metabolism and cardiac (dys)function in pathologies such as cardiac hypertrophy, heart failure and diabetic cardiomyopathy. He has published over 110 peer-review papers with a H-index of 50. His research is supported by different grants from the Federal and Regional Governments, FNRS, WELBIO and UCLouvain. He was/is board member of several international scientific organizations (Working group of myocardial function of the European Society of cardiology, French Society of Cardiology, Society for Heart and Vascular Metabolism, Fondation de France) and scientific journals (Am. J. Physiol. Heart and Circul. Physiol., PlosONE).

Prof Lea Delbridge leads the Cardiac Phenomics Laboratory in the Department of Physiology at the University of Melbourne. Her research goals are to understand structural and functional cardiopathology in different forms of diabetic and hypertrophic cardiomyopathy. Her current work is supported by the National Health and Medical Research Council of Australia and the Australian Research Council. Lea has published ~ 160 peer reviewed papers in many top-discipline journals.
Lea completed her PhD at the University of Melbourne, and had training positions at Dalhousie University (Halifax, Canada) and also at Loyola University (Chicago, USA) as an International Fellow of the American Heart Association. She is elected World Council Secretary General of the International Society of Heart Research (ISHR) and was President of the Australasian ISHR Section 2007-2013.
Lea is an elected Fellow of the Cardiac Society of Aust & New Zealand (CSANZ) and of the ISHR. Lea served on the Scientific Committee of the CSANZ, is appointed to the Board of the International Union of Physiological Sciences and completed two terms as Council member of the Australian Physiological Society (AuPS). She is an editorial board member for a number of international journals, including J Molecular & Cellular Cardiology, Frontiers in Physiology, Curr Opin Physiol and the Am J Physiol (Heart.). She serves as the Chair of the Scientific Program for the 2022 ISHR Berlin Congress.

Prof Lea Delbridge leads the Cardiac Phenomics Laboratory in the Department of Physiology at the University of Melbourne. Her research goals are to understand structural and functional cardiopathology in different forms of diabetic and hypertrophic cardiomyopathy. Her current work is supported by the National Health and Medical Research Council of Australia and the Australian Research Council. Lea has published ~ 160 peer reviewed papers in many top-discipline journals.
Lea completed her PhD at the University of Melbourne, and had training positions at Dalhousie University (Halifax, Canada) and also at Loyola University (Chicago, USA) as an International Fellow of the American Heart Association. She is elected World Council Secretary General of the International Society of Heart Research (ISHR) and was President of the Australasian ISHR Section 2007-2013.
Lea is an elected Fellow of the Cardiac Society of Aust & New Zealand (CSANZ) and of the ISHR. Lea served on the Scientific Committee of the CSANZ, is appointed to the Board of the International Union of Physiological Sciences and completed two terms as Council member of the Australian Physiological Society (AuPS). She is an editorial board member for a number of international journals, including J Molecular & Cellular Cardiology, Frontiers in Physiology, Curr Opin Physiol and the Am J Physiol (Heart.). She serves as the Chair of the Scientific Program for the 2022 ISHR Berlin Congress.

Dr. Enríquez graduated from Biological Sciences at the Autonomous University of Madrid in 1986, obtaining a doctorate in Biochemistry from the University of Zaragoza in 1992 with an outstanding cum laude. His doctoral thesis, carried out in the laboratory of Dr. Montoya, focused on the study of various aspects of the biogenesis of mitochondrial DNA (mtDNA).
In 1993 he moved to the laboratory of Dr. G. Attadi at the California Institute of Technology (CALTECH) as a postdoctoral researcher, first with competitive grants from the Spanish Government and later hired by CALTECH itself as a senior research fellow. It is at this stage when Dr. Enríquez investigates the pathogenic action of mutations in human mitochondrial tRNAs. His work during this period contributed to defining the molecular mechanism underlying this phenomenon and helped establish a general methodology for the study of mitochondrial tRNAs. This methodology has been applied in mitochondrial biogenesis studies, as well as in the analysis of diseases related to mtDNA.
In 1997 he returned to Spain with a reincorporation contract from the University of Zaragoza as an independent researcher and founded his own research group. In 2007 he got his position as Full Professor.In this period, he made important contributions to the understanding of the biogenesis of the oxidative phosphorylation system, and the pathological consequences of the alteration of mitochondrial function. His work focused on two main lines: 1) The understanding of the integration of the mitochondrial and nuclear genomes to obtain an adequate cellular respiratory function. Special attention was paid to the functional relevance of the genetic variability of mitochondrial DNA in humans and animals. 2) The re-evaluation of the universally accepted models of structural organization and of the mitochondrial electronic transport chain.
In 2009, Dr. Enríquez moved to the National Center for Cardiovascular Research - CNIC where he continued his previous lines of work and aimed to elucidate the molecular mechanisms of mitochondrial dysfunction in cardiovascular disease and ischemic processes.
Altogether, Dr. Enríquez has published 143 scientific papers and have an index H = 53 (according to SCOPUS).
The success of Dr Enríquez's work is reflected in his international leadership that has consolidated him as an international benchmark in his field. In addition, Dr. Enríquez has always demonstrated a vocation for training new scientists and supporting their research career. Proof of this are the 17 supervised theses and the 3 that he has underway, as well as his work as a professor in his Chair, in addition to his participation in numerous masters and courses.

Dr. Enríquez graduated from Biological Sciences at the Autonomous University of Madrid in 1986, obtaining a doctorate in Biochemistry from the University of Zaragoza in 1992 with an outstanding cum laude. His doctoral thesis, carried out in the laboratory of Dr. Montoya, focused on the study of various aspects of the biogenesis of mitochondrial DNA (mtDNA).
In 1993 he moved to the laboratory of Dr. G. Attadi at the California Institute of Technology (CALTECH) as a postdoctoral researcher, first with competitive grants from the Spanish Government and later hired by CALTECH itself as a senior research fellow. It is at this stage when Dr. Enríquez investigates the pathogenic action of mutations in human mitochondrial tRNAs. His work during this period contributed to defining the molecular mechanism underlying this phenomenon and helped establish a general methodology for the study of mitochondrial tRNAs. This methodology has been applied in mitochondrial biogenesis studies, as well as in the analysis of diseases related to mtDNA.
In 1997 he returned to Spain with a reincorporation contract from the University of Zaragoza as an independent researcher and founded his own research group. In 2007 he got his position as Full Professor.In this period, he made important contributions to the understanding of the biogenesis of the oxidative phosphorylation system, and the pathological consequences of the alteration of mitochondrial function. His work focused on two main lines: 1) The understanding of the integration of the mitochondrial and nuclear genomes to obtain an adequate cellular respiratory function. Special attention was paid to the functional relevance of the genetic variability of mitochondrial DNA in humans and animals. 2) The re-evaluation of the universally accepted models of structural organization and of the mitochondrial electronic transport chain.
In 2009, Dr. Enríquez moved to the National Center for Cardiovascular Research - CNIC where he continued his previous lines of work and aimed to elucidate the molecular mechanisms of mitochondrial dysfunction in cardiovascular disease and ischemic processes.
Altogether, Dr. Enríquez has published 143 scientific papers and have an index H = 53 (according to SCOPUS).
The success of Dr Enríquez's work is reflected in his international leadership that has consolidated him as an international benchmark in his field. In addition, Dr. Enríquez has always demonstrated a vocation for training new scientists and supporting their research career. Proof of this are the 17 supervised theses and the 3 that he has underway, as well as his work as a professor in his Chair, in addition to his participation in numerous masters and courses.

Dieter Fuchs, PhD is responsible for strategic planning and novel preclinical imaging applications for Fujifilm VisualSonics. Before joining Fujifilm VisualSonics in 2009, his PhD studies at Uppsala University, Sweden and subsequent post doc work at the Karolinska Institute in Stockholm. He was teaching anatomy and the cardiovascular system at Uppsala Medical School.

Dieter Fuchs, PhD is responsible for strategic planning and novel preclinical imaging applications for Fujifilm VisualSonics. Before joining Fujifilm VisualSonics in 2009, his PhD studies at Uppsala University, Sweden and subsequent post doc work at the Karolinska Institute in Stockholm. He was teaching anatomy and the cardiovascular system at Uppsala Medical School.

Dr. Anne Garnier is currently Professor in Human Physiology at the Faculty of Pharmacy of the University of Paris-Saclay (Châtenay-Malabry, France). She is also scientific director of UMS-IPSIT, a mixed service unit comprising 11 technical platforms, at the Faculty of Pharmacy of the University of Paris-Saclay. Since 2010, she is co-leader of the research group “Energy signaling and cardiovascular pathophysiology” in INSERM - University Paris-Saclay research unit UMR-S1180. Her main research field is focused on the mitochondrial life cycle (mitochondrial biogenesis, network dynamics, and clearance) and its regulation in the healthy and failing heart in order to develop a metabolic therapy of heart failure based on the regeneration of mitochondrial function. The research group has shown that the decrease in oxidative capacities of cardiac and skeletal muscles is associated with a downregulation of the transcriptional cascade of mitochondrial biogenesis. Using unique transgenic male and female mice models, the group is studying now the signaling pathways involved in the control mitochondrial biogenesis and function, mainly AMPK and sirtuin 1. Her research was/is funded by Fondation pour la Recherche Médicale (FRM), Fondation de France and Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT LabEx).

Dr. Anne Garnier is currently Professor in Human Physiology at the Faculty of Pharmacy of the University of Paris-Saclay (Châtenay-Malabry, France). She is also scientific director of UMS-IPSIT, a mixed service unit comprising 11 technical platforms, at the Faculty of Pharmacy of the University of Paris-Saclay. Since 2010, she is co-leader of the research group “Energy signaling and cardiovascular pathophysiology” in INSERM - University Paris-Saclay research unit UMR-S1180. Her main research field is focused on the mitochondrial life cycle (mitochondrial biogenesis, network dynamics, and clearance) and its regulation in the healthy and failing heart in order to develop a metabolic therapy of heart failure based on the regeneration of mitochondrial function. The research group has shown that the decrease in oxidative capacities of cardiac and skeletal muscles is associated with a downregulation of the transcriptional cascade of mitochondrial biogenesis. Using unique transgenic male and female mice models, the group is studying now the signaling pathways involved in the control mitochondrial biogenesis and function, mainly AMPK and sirtuin 1. Her research was/is funded by Fondation pour la Recherche Médicale (FRM), Fondation de France and Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT LabEx).

Dr. Erich Gnaiger is founder and CEO of Oroboros Instruments, developer and distributer of O2k-Technology for high-resolution respirometry. His scientific and technical expertise in mitochondrial physiology and pathology, microcalorimetry and biological thermodynamics, stems from his PhD in zoophysiology, limnology and biochemistry from the University of Innsbruck, where he also completed his habilitation. Currently he is leading the EU H2020 Framework project ‘NextGen-O2k’, developing the all-in-one instrument for measuring Q- and NADH-redox states and photosynthesis alongside oxygen consumption, the NextGen-O2k. Dr. Gnaiger and Oroboros are partners in several nationally and internationally funded projects.
His active involvement in the mitochondrial research community extends beyond project collaborations. He is also the initiator and chairman of the International Mitochondrial Physiology Society (MiPsociety),and was Chair of the COST Action CA15203 MitoEAGLE 2016-2021. Additionally he serves as the editor of MitoFit Preprints – the open access preprint server for mitochondrial physiology and bioenergetics, and Bioenergetics Communications – the open access, open peer-review journal of the MiPsociety.

Dr. Erich Gnaiger is founder and CEO of Oroboros Instruments, developer and distributer of O2k-Technology for high-resolution respirometry. His scientific and technical expertise in mitochondrial physiology and pathology, microcalorimetry and biological thermodynamics, stems from his PhD in zoophysiology, limnology and biochemistry from the University of Innsbruck, where he also completed his habilitation. Currently he is leading the EU H2020 Framework project ‘NextGen-O2k’, developing the all-in-one instrument for measuring Q- and NADH-redox states and photosynthesis alongside oxygen consumption, the NextGen-O2k. Dr. Gnaiger and Oroboros are partners in several nationally and internationally funded projects.
His active involvement in the mitochondrial research community extends beyond project collaborations. He is also the initiator and chairman of the International Mitochondrial Physiology Society (MiPsociety),and was Chair of the COST Action CA15203 MitoEAGLE 2016-2021. Additionally he serves as the editor of MitoFit Preprints – the open access preprint server for mitochondrial physiology and bioenergetics, and Bioenergetics Communications – the open access, open peer-review journal of the MiPsociety.

Lisa Heather is an Associate Professor and British Heart Foundation Fellow at the University of Oxford. She completed an undergraduate degree in Medical Biochemistry at the University of Surrey. She studied for her DPhil at the Department of Physiology, Anatomy and Genetics at the University of Oxford, investigating the effects of heart failure on cardiac substrate metabolism.
Lisa was awarded a RD Lawrence Early Career Fellowship by Diabetes UK in 2011, followed by a British Heart Foundation Basic Science Intermediate Fellowship in 2018. Her research group studies cardiac metabolic dysfunction in type 2 diabetes. Her current research focuses on the signalling roles metabolites play within the heart, and how these signalling pathways become dysfunction in type 2 diabetic heart. She was the recipient of the Innovators in Diabetes Award in 2012, Lilly Diabetes Award in 2013 and the Bayliss-Starling Award from the Physiological Society in 2016.

Lisa Heather is an Associate Professor and British Heart Foundation Fellow at the University of Oxford. She completed an undergraduate degree in Medical Biochemistry at the University of Surrey. She studied for her DPhil at the Department of Physiology, Anatomy and Genetics at the University of Oxford, investigating the effects of heart failure on cardiac substrate metabolism.
Lisa was awarded a RD Lawrence Early Career Fellowship by Diabetes UK in 2011, followed by a British Heart Foundation Basic Science Intermediate Fellowship in 2018. Her research group studies cardiac metabolic dysfunction in type 2 diabetes. Her current research focuses on the signalling roles metabolites play within the heart, and how these signalling pathways become dysfunction in type 2 diabetic heart. She was the recipient of the Innovators in Diabetes Award in 2012, Lilly Diabetes Award in 2013 and the Bayliss-Starling Award from the Physiological Society in 2016.

Howy Jacobs is Professor of Molecular Biology in Tampere University, Finland (since 1996). Educated in Cambridge, Glasgow and Caltech, he has spent most of his career studying aspects of mitochondria, including mitochondrial DNA transactions, the pathophysiology and molecular mechanisms of mitochondrial disease, and the properties of alternative respiratory chain enzymes. Most recently he has been studying the thermobiology of mitochondria, the topic of his talk to SHVM 2021. As well as winning a number of research awards, Howy has been active in the affairs of EMBO, notably as Chief Editor of EMBO Reports (2009-2014), and has undertaken numerous other tasks in scientific publication, conferencing and public communication.

Howy Jacobs is Professor of Molecular Biology in Tampere University, Finland (since 1996). Educated in Cambridge, Glasgow and Caltech, he has spent most of his career studying aspects of mitochondria, including mitochondrial DNA transactions, the pathophysiology and molecular mechanisms of mitochondrial disease, and the properties of alternative respiratory chain enzymes. Most recently he has been studying the thermobiology of mitochondria, the topic of his talk to SHVM 2021. As well as winning a number of research awards, Howy has been active in the affairs of EMBO, notably as Chief Editor of EMBO Reports (2009-2014), and has undertaken numerous other tasks in scientific publication, conferencing and public communication.

Werner Kammerloher studied chemistry at the Technical University of Munich and completed his dissertation at the Institute for Biochemistry at the Ludwig Maximilians University in Munich. For the last 10 years he was responsible for Seahorse Inc. and later Agilent Technologies for the sales of Seahorse instruments in Germany and Austria.

Werner Kammerloher studied chemistry at the Technical University of Munich and completed his dissertation at the Institute for Biochemistry at the Ludwig Maximilians University in Munich. For the last 10 years he was responsible for Seahorse Inc. and later Agilent Technologies for the sales of Seahorse instruments in Germany and Austria.

Dr. Hyoung Kyu Kim is currently a professor at the Cardiovascular and Metabolic Diseases Center (CMDC), Inje University. From 2008 to 2012 he conducted research as a postdoctoral fellow and research professor at the CMDC. He was appointed professor at the CMDC, Inje University School of Medicine in 2012, where he continues to this day. During his doctoral course, he was interested in proteomics and mitochondrial research and conducted related research. After his doctorate degree, based on the regulation of proteomics and mitochondrial function, he investigated the association between mitochondrial dysfunction and disease in cardiovascular and metabolic diseases and the regulation of mitochondrial function. Research on treatment strategies through He has published more than 110 papers in the field of mitochondrial and cardiovascular and metabolic diseases. Since he first attended the SHVM 2016 symposium in Beijing with the introduction of Professor Dale Abel, he has been attending the regular SVHM symposium every year until now, and is serving as a committee member of the Seoul SHVM symposium in 2022.

Dr. Hyoung Kyu Kim is currently a professor at the Cardiovascular and Metabolic Diseases Center (CMDC), Inje University. From 2008 to 2012 he conducted research as a postdoctoral fellow and research professor at the CMDC. He was appointed professor at the CMDC, Inje University School of Medicine in 2012, where he continues to this day. During his doctoral course, he was interested in proteomics and mitochondrial research and conducted related research. After his doctorate degree, based on the regulation of proteomics and mitochondrial function, he investigated the association between mitochondrial dysfunction and disease in cardiovascular and metabolic diseases and the regulation of mitochondrial function. Research on treatment strategies through He has published more than 110 papers in the field of mitochondrial and cardiovascular and metabolic diseases. Since he first attended the SHVM 2016 symposium in Beijing with the introduction of Professor Dale Abel, he has been attending the regular SVHM symposium every year until now, and is serving as a committee member of the Seoul SHVM symposium in 2022.

José López-Barneo is a professor of Medical Physiology and Biophysics at the University of Seville Medical School, Research Director of the University Hospital and founder Director of the Institute of Biomedicine of Seville. He did postdoctoral stays at the CNRS (Paris), University of Pennsylvania Medical School (Philadelphia) and New York University Medical Center (New York), and has been a visiting professor at Stanford University School of Medicine (Palo Alto, Ca) and Columbia University (New York). Dr. López-Barneo main research interests are related to the study of the mechanisms of acute oxygen sensing in mammals, specifically by the carotid body and other peripheral chemoreceptor organs, as well as the cellular adaptations to hypoxia. He also works on the modulation by hypoxia of the peripheral and central neurogenic centers and the molecular bases of dopaminergic neuroprotection and neurodegeneration. Dr. López-Barneo has served as an editor in the Journal of Physiology, Pflügers Archiv/European Journal of Physiology, Physiology, and Physiological Reviews. Dr. López-Barneo is past President of the Spanish Neuroscience Association and the Spanish Society for Gene and Cell Therapy. He is a member of the Academia Europea and the European Molecular Biology Organization. For over 30 years Dr. López-Barneo’s laboratory has been supported by grants from the Spanish Government, the Juan March and Botín Foundations, European Union and the European Research Council.

José López-Barneo is a professor of Medical Physiology and Biophysics at the University of Seville Medical School, Research Director of the University Hospital and founder Director of the Institute of Biomedicine of Seville. He did postdoctoral stays at the CNRS (Paris), University of Pennsylvania Medical School (Philadelphia) and New York University Medical Center (New York), and has been a visiting professor at Stanford University School of Medicine (Palo Alto, Ca) and Columbia University (New York). Dr. López-Barneo main research interests are related to the study of the mechanisms of acute oxygen sensing in mammals, specifically by the carotid body and other peripheral chemoreceptor organs, as well as the cellular adaptations to hypoxia. He also works on the modulation by hypoxia of the peripheral and central neurogenic centers and the molecular bases of dopaminergic neuroprotection and neurodegeneration. Dr. López-Barneo has served as an editor in the Journal of Physiology, Pflügers Archiv/European Journal of Physiology, Physiology, and Physiological Reviews. Dr. López-Barneo is past President of the Spanish Neuroscience Association and the Spanish Society for Gene and Cell Therapy. He is a member of the Academia Europea and the European Molecular Biology Organization. For over 30 years Dr. López-Barneo’s laboratory has been supported by grants from the Spanish Government, the Juan March and Botín Foundations, European Union and the European Research Council.

Satoaki Matoba MD, PhD is a Professor of the Department of Cardiovascular Medicine at Kyoto Prefectural University of Medicine, Japan. He started his research about the energy metabolism and ischemia/reperfusion injury of the heart and earned his PhD in 1999. He did his postdoctoral training at the cardiology department of NHLBI/NIH. He found that tumor suppresser, p53 regulates mitochondrial respiration, which provided an explanation for the Warburg effect and offered several clues to research the relation of p53, aging and metabolism. After coming back to Japan, he showed cytosolic p53 disturbs the process of mitophagy through an inhibitory interaction with Parkin and induces mitochondrial dysfunction, which are important in cardiac aging and pancreatic beta-cell viability. In 2017 he  demonstrated that D-?-hydroxybutyrate dehydrogenase I (Bdh1), an enzyme that catalyzes the NAD+/NADH coupled interconversion of acetoacetate and ?-hydroxybutyrate, was increased in the heart after transverse aortic constriction. He revealed that ketone body oxidation increased in failing hearts, and increased ketone body utilization decreased oxidative stress and protected against heart failure. Now this mechanism became popular by clinical studies of SGLT2 inhibitor. His current work addresses the effect of D-amino acid on the failing heart and cardiovascular aging. He also published the paper that originally engineered ACE2 protein to protect hamsters from SARS-CoV-2 infection, decreased lung virus titers and pathology.

Satoaki Matoba MD, PhD is a Professor of the Department of Cardiovascular Medicine at Kyoto Prefectural University of Medicine, Japan. He started his research about the energy metabolism and ischemia/reperfusion injury of the heart and earned his PhD in 1999. He did his postdoctoral training at the cardiology department of NHLBI/NIH. He found that tumor suppresser, p53 regulates mitochondrial respiration, which provided an explanation for the Warburg effect and offered several clues to research the relation of p53, aging and metabolism. After coming back to Japan, he showed cytosolic p53 disturbs the process of mitophagy through an inhibitory interaction with Parkin and induces mitochondrial dysfunction, which are important in cardiac aging and pancreatic beta-cell viability. In 2017 he  demonstrated that D-?-hydroxybutyrate dehydrogenase I (Bdh1), an enzyme that catalyzes the NAD+/NADH coupled interconversion of acetoacetate and ?-hydroxybutyrate, was increased in the heart after transverse aortic constriction. He revealed that ketone body oxidation increased in failing hearts, and increased ketone body utilization decreased oxidative stress and protected against heart failure. Now this mechanism became popular by clinical studies of SGLT2 inhibitor. His current work addresses the effect of D-amino acid on the failing heart and cardiovascular aging. He also published the paper that originally engineered ACE2 protein to protect hamsters from SARS-CoV-2 infection, decreased lung virus titers and pathology.

Deb Muoio is professor in the Departments of Medicine and Pharmacology & Cancer Biology, George Barth Geller Distinguished Professor of Cardiovascular Disease, and director of basic science research at the Duke Molecular Physiology Institute (DMPI) at Duke University. She is viewed nationally and internationally as a leader in the fields of diabetes, obesity, exercise physiology, and mitochondrial energy metabolism. Her laboratory investigates mechanisms of metabolic regulation, with emphasis on molecular events that link lifestyle factors such as over nutrition and physical inactivity to metabolic disorders, including obesity, diabetes, and heart failure. Her program features a translational approach that combines work in animal and cell-based models with human studies, using genetic engineering, molecular biology and mass spectrometry-based metabolomics and proteomics as tools to understand the interplay between mitochondrial physiology and cardiometabolic health. Her laboratory developed a sophisticated platform for deep and comprehensive assessment of mitochondrial bioenergetics and energy transduction. Her team is integrating this new platform with metabolomics, proteomics, and metabolic flux analysis to gain insights into mechanisms by which mitochondria modulate insulin action and metabolic resilience. She has published more than 120 papers in prominent journals such as Cell, Cell Metabolism, Circulation, Circulation Research, Diabetes, and JCI Insight. Dr. Muoio’s laboratory has enjoyed longstanding support from the NIDDK and NHLBI.

Deb Muoio is professor in the Departments of Medicine and Pharmacology & Cancer Biology, George Barth Geller Distinguished Professor of Cardiovascular Disease, and director of basic science research at the Duke Molecular Physiology Institute (DMPI) at Duke University. She is viewed nationally and internationally as a leader in the fields of diabetes, obesity, exercise physiology, and mitochondrial energy metabolism. Her laboratory investigates mechanisms of metabolic regulation, with emphasis on molecular events that link lifestyle factors such as over nutrition and physical inactivity to metabolic disorders, including obesity, diabetes, and heart failure. Her program features a translational approach that combines work in animal and cell-based models with human studies, using genetic engineering, molecular biology and mass spectrometry-based metabolomics and proteomics as tools to understand the interplay between mitochondrial physiology and cardiometabolic health. Her laboratory developed a sophisticated platform for deep and comprehensive assessment of mitochondrial bioenergetics and energy transduction. Her team is integrating this new platform with metabolomics, proteomics, and metabolic flux analysis to gain insights into mechanisms by which mitochondria modulate insulin action and metabolic resilience. She has published more than 120 papers in prominent journals such as Cell, Cell Metabolism, Circulation, Circulation Research, Diabetes, and JCI Insight. Dr. Muoio’s laboratory has enjoyed longstanding support from the NIDDK and NHLBI.

Claudia Oerther is responsible for a team that is selling preclinical MRI, PET, SPECT, CT and MPI in Europe, India, Middle East, and Africa (EIMEA) for Bruker based in Ettlingen, near Karlsruhe in Germany. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels.
Dr. Claudia Oerther has a degree in physics and has earned her PhD in MR Physics at Free University Berlin, Germany in perfusion measurements in experimental glioma in rats.
She started to work for Bruker in 2021 as an application scientist with a focus on perfusion measurements, cardiac applications, and spectroscopy applications. During this time, she was responsible for developing animal handling systems (animal beds, automatic positioning systems and monitoring systems) and program processing tools for perfusion measurements in MRI. Her focus was the generation of a package of cardiac methods offering white blood contrast, black-blood contrast grid tagging and self-gating methods without the need of using ecg electrodes 2007 she became a marketing manager, was promoted to the director of marketing and sales for the MRI area and 2013 she was working as the global sales manager for MRI. Since 2015 she expanded her horizon with PET, SPECT, CT, optical imaging and MPI and was promoted to director of sales for all these imaging modalities in EIMEA.

Claudia Oerther is responsible for a team that is selling preclinical MRI, PET, SPECT, CT and MPI in Europe, India, Middle East, and Africa (EIMEA) for Bruker based in Ettlingen, near Karlsruhe in Germany. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels.
Dr. Claudia Oerther has a degree in physics and has earned her PhD in MR Physics at Free University Berlin, Germany in perfusion measurements in experimental glioma in rats.
She started to work for Bruker in 2021 as an application scientist with a focus on perfusion measurements, cardiac applications, and spectroscopy applications. During this time, she was responsible for developing animal handling systems (animal beds, automatic positioning systems and monitoring systems) and program processing tools for perfusion measurements in MRI. Her focus was the generation of a package of cardiac methods offering white blood contrast, black-blood contrast grid tagging and self-gating methods without the need of using ecg electrodes 2007 she became a marketing manager, was promoted to the director of marketing and sales for the MRI area and 2013 she was working as the global sales manager for MRI. Since 2015 she expanded her horizon with PET, SPECT, CT, optical imaging and MPI and was promoted to director of sales for all these imaging modalities in EIMEA.

Moa Persson is a Sales Manager at the Swedish med-tech company Symcel and has a long experience within the life-science sector. She has a Bachelor Degree in Biotechnology Engineering and a MSC in Bioentrepreneurship and Business from Chalmers University of Technology, Gothenburg.
At her current position at Symcel, Moa is responsible for driving all operative sales world-wide. SymCel is offering the unique instrument, the calScreenerTM - a label free cell-based assay system that measures the heat flux from living cells in real time. The company is currently in a very expansive phase and Moa is working closely with researchers within a broad range of field, such as cancer metabolism, microbiology, obesity and quality control.
Prior entering the career within sales, Moa was working as a Research Associate at Karolinska Institute within the field of clinical physiology. The main aim with the research conducted was to examine gene expression response to profound metabolic and hormonal stress induced by acute sprint exercise.
One of her greatest interest is to link how novel commercial discoveries can help address complex scientific challenges. Moa has a great drive and curiosity to use her both commercial and scientific mindset to try to find new innovative approaches to enhance scientific discoveries.
Furthermore, Moa is an elite athlete and are competing in Muay Thai on a national level. This is a great interest of hers- providing a nice contrast and balance in life.

Moa Persson is a Sales Manager at the Swedish med-tech company Symcel and has a long experience within the life-science sector. She has a Bachelor Degree in Biotechnology Engineering and a MSC in Bioentrepreneurship and Business from Chalmers University of Technology, Gothenburg.
At her current position at Symcel, Moa is responsible for driving all operative sales world-wide. SymCel is offering the unique instrument, the calScreenerTM - a label free cell-based assay system that measures the heat flux from living cells in real time. The company is currently in a very expansive phase and Moa is working closely with researchers within a broad range of field, such as cancer metabolism, microbiology, obesity and quality control.
Prior entering the career within sales, Moa was working as a Research Associate at Karolinska Institute within the field of clinical physiology. The main aim with the research conducted was to examine gene expression response to profound metabolic and hormonal stress induced by acute sprint exercise.
One of her greatest interest is to link how novel commercial discoveries can help address complex scientific challenges. Moa has a great drive and curiosity to use her both commercial and scientific mindset to try to find new innovative approaches to enhance scientific discoveries.
Furthermore, Moa is an elite athlete and are competing in Muay Thai on a national level. This is a great interest of hers- providing a nice contrast and balance in life.

Claudia Prothmann received her PhD from the Ludwig-Maximilian-University Munich for her work on the communication of bacteria in 2012. She worked on the single cell level in the group of Prof. Kirsten Jung. Between 2013 and 2016, she accomplished her postdoctoral studies on Next Generation Sequencing at the Helmholtz Center Munich. After a short period as an account manager, she returned to the Helmholtz Center Munich to coordinate the Helmholtz Association’s future topic “Aging and Metabolic Programming (AMPro)” from 2017 to 2020. Since the beginning of this year Dr. Prothmann works as a Scientific Specialist and Field Marketing Manager for Genomics at Merck Chemicals GmbH. She is responsible for academic customer in Germany, Austria and Switzerland.

Claudia Prothmann received her PhD from the Ludwig-Maximilian-University Munich for her work on the communication of bacteria in 2012. She worked on the single cell level in the group of Prof. Kirsten Jung. Between 2013 and 2016, she accomplished her postdoctoral studies on Next Generation Sequencing at the Helmholtz Center Munich. After a short period as an account manager, she returned to the Helmholtz Center Munich to coordinate the Helmholtz Association’s future topic “Aging and Metabolic Programming (AMPro)” from 2017 to 2020. Since the beginning of this year Dr. Prothmann works as a Scientific Specialist and Field Marketing Manager for Genomics at Merck Chemicals GmbH. She is responsible for academic customer in Germany, Austria and Switzerland.

Natascha Sommer, MD, PhD leads the research group on mitochondrial physiology and pathology in the lung of the Excellence Cluster “Cardio-Pulmonary Institute” in Giessen, Germany. She is also a medical doctor focusing on pulmonary vascular and airway diseases and works as senior physician in the Department of Pneumology at the Justus-Liebig University Giessen. In the last decade, she dedicated her work to hypoxia-induced physiological signaling in the pulmonary vasculature and pathological mechanisms underlying pulmonary vascular and airway diseases with a focus on mitochondrial superoxide-dependent mechanisms. In 2018, she received the basic research award of the German Society of Pneumology for her investigations on reactive oxygen species and nitric oxide signaling in hypoxic pulmonary vasoconstriction and pulmonary hypertension.

Natascha Sommer, MD, PhD leads the research group on mitochondrial physiology and pathology in the lung of the Excellence Cluster “Cardio-Pulmonary Institute” in Giessen, Germany. She is also a medical doctor focusing on pulmonary vascular and airway diseases and works as senior physician in the Department of Pneumology at the Justus-Liebig University Giessen. In the last decade, she dedicated her work to hypoxia-induced physiological signaling in the pulmonary vasculature and pathological mechanisms underlying pulmonary vascular and airway diseases with a focus on mitochondrial superoxide-dependent mechanisms. In 2018, she received the basic research award of the German Society of Pneumology for her investigations on reactive oxygen species and nitric oxide signaling in hypoxic pulmonary vasoconstriction and pulmonary hypertension.